NCT05624099

Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.

Prospective Single-arm, Exploratory, Multicenter Phase II Clinical Study of Camrelizumab Combined With Chemoradiotherapy in the Treatment of Advanced First-line Esophageal Phosphorous Carcinoma

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 75 (estimated)
• Sponsor: Fujian Cancer Hospital · Other Government
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a prospective single-arm exploratory clinical study. The efficacy and safety of camrelizumab combined with chemoradiotherapy and camrelizumab combined with chemotherapy were evaluated in patients with advanced esophageal cancer who had not previously received any systemic antitumor therapy for esophageal cancer.

Conditions

• Esophageal Neoplasms
• Esophageal Diseases
• Digestive System Neoplasms

Interventions

Type	Name	Description
DRUG	camrelizumab	200mg intravenous drip d1q3w
DRUG	Paclitaxel drugs	150mg/m2 d1 q3w
DRUG	Platinum drug	Cisplatin, carboplatin, nedaplatin and other platinum drugs
RADIATION	Radiation	Dose: 5040cGy/28f

Timeline

• Start date: 2023-08-01
• Primary completion: 2025-12-01
• Completion: 2027-12-31
• First posted: 2022-11-21
• Last updated: 2023-10-19

Locations

1 site across 1 country: China